| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Research |



,**

* Service dHépatogastroenterologie et Nutrition, Clinique Résidence du Parc, Marseille,
Service de Néphrologie, Hôpital Edouard Herriot, Lyon,
INSERM-E0221 Bioénergétique Fondamentale et Appliquée, Grenoble,
Université Bordeaux2 and CHU de Bordeaux and ** AURAD Aquitaine, Bordeaux, || Service de Néphrologie, Centre Hospitalier, Dunkerque, and ¶ Service de Néphrologie, Hôpital Lapeyronnie, Montpellier, France
Correspondence: Dr. Noël J.M. Cano, CRNH Auvergne, 58 Rue Montalembert, BP 321, 63009 Clermont-Ferrand cedex 1, France. Phone: +33-4-7360-8250; Fax: +33-4-7360-8255; E-mail: ncano{at}clermont.inra.fr
Received for publication February 11, 2007. Accepted for publication May 3, 2007.
Although intradialytic parenteral nutrition (IDPN) is a method used widely to combat protein-calorie malnutrition in hemodialysis patients, its effect on survival has not been thoroughly studied. We conducted a prospective, randomized trial in which 186 malnourished hemodialysis patients received oral nutritional supplements with or without 1 year of IDPN. IDPN did not improve 2-year mortality (primary end point), hospitalization rate, Karnofsky score, body mass index, or laboratory markers of nutritional status. Instead, both groups demonstrated improvement in body mass index and the nutritional parameters serum albumin and prealbumin (P < 0.05). Multivariate analysis showed that an increase in prealbumin of >30 mg/L within 3 months, a marker of nutritional improvement, independently predicted a 54% decrease in 2-year mortality, as well as reduced hospitalizations and improved general well-being as measured by the Karnofsky score. Therefore, although we found no definite advantage of adding IDPN to oral nutritional supplementation, this is the first prospective study demonstrating that an improvement in prealbumin during nutritional therapy is associated with a decrease in morbidity and mortality in malnourished hemodialysis patients.
This article has been cited by other articles:
![]() |
D. Fouque, J. McKenzie, R. de Mutsert, R. Azar, D. Teta, M. Plauth, N. Cano, and the Renilon Multicentre Trial Study Group Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2902 - 2910. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Ikizler, P. Stenvinkel, and B. Lindholm Resolved: Being Fat Is Good for Dialysis Patients: The Godzilla Effect: Pro J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1059 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673